DYAX REPORTS HAE STUDY RESULTS

Dyax has announced positive topline data from an open-label Phase II clinical trial, referred to as Edema2, with DX-88 for the treatment of hereditary angioedema (HAE).

In the study, DX-88 was well-tolerated and successful in treating all types of attacks, including peripheral, abdominal and life-threatening laryngeal attacks, whether administered through the intravenous or subcutaneous route of administration. DX-88 is being developed in a joint venture with Genzyme for the treatment of HAE, a debilitating and life-threatening inflammatory condition characterized by unpredictable attacks of severe pain and swelling.